University of Alabama
Birmingham, Alabama, United States
NCT Number: NCT00001701
Innate immunity plays an important role for fungal recognition and initiation of fungicidal activity. We hypothesize that subtle differences in different molecules of innate immunity may contribute to either the predisposition or clinical course of infection with Cryptococcus neoformans. To test this hypothesis, we propose to analyze the allelic frequencies of 15 different genes (mannose binding lectin, Fc-gamma receptor IIa and IIb, Fc-gamma receptors IIIa and IIIb, myeloperoxidase, tumor necrosis factor-alpha and -beta, interleukin 1A and 1B, interleukin-1 receptor antagonist, interleukin-10, NRAMP-1, chitotriosidase, and chemokine receptor 5) and their intragenic polymorphic forms and to compare this data to the incidence and severity of C neoformans infection. With this study we hope to identify a group of molecules of innate immunity which influence the risk and severity of invasive C neoformans infection.
Looking for future studies?
Notify MeAll sexes
Observational
Birmingham, Alabama, United States
Innate immunity plays an important role for fungal recognition and initiation of fungicidal activity. We hypothesize that subtle differences in different molecules of innate immunity may contribute to either the predisposition or clinical course of infection with Cryptococcus neoformans. To test this hypothesis, we propose to analyze the allelic frequencies of 15 different genes (mannose binding lectin, Fc-gamma receptor IIa and IIb, Fc-gamma receptors IIIa and IIIb, myeloperoxidase, tumor necrosis factor-alpha and -beta, interleukin 1A and 1B, interleukin-1 receptor antagonist, interleukin-10, NRAMP-1, chitotriosidase, and chemokine receptor 5) and their intragenic polymorphic forms and to compare this data to the incidence and severity of C neoformans infection. With this study we hope to identify a group of molecules of innate immunity which influence the risk and severity of invasive C neoformans infection.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Patients diagnosed with Cryptococcus neoformans infection will be identified from a data base overseen by Dr. Peter Pappas.
Only patients diagnosed and treated in the United States and Canada will be included in this analysis.
Only patients who are not coinfected with HIV will be included in the study.
Patient samples will be collected and clinical data will be evaluated only after signed informed consent has been obtained.
National Cancer Institute (NCI)
Nih
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05707156
Aspergillosis, Bacterial Infections and Mycoses
Denver, Colorado, United States
View Trial DetailsNCT04033718
Acquired Immunodeficiency Syndrome, Actinomycetales Infections
Lusaka, Zambia
View Trial DetailsNCT01535469
Acquired Immunodeficiency Syndrome, Bacterial Infections and Mycoses
Kampala, Uganda
View Trial DetailsNCT03993093
Actinomycetales Infections, Bacterial Infections
Khagaria, Bihar, India
View Trial Details